Francesco Puglisi

Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction.

Carola Riva, Paola Minetto, Giada Zecchetti, Stefano Nicoletta et autres

Abstract Introduction Acute Myeloid Leukemia (AML) is a heterogeneous disease, driven by the serial acquisition of somatic mutations, that may be evolve (s-AML) from a previous myelodysplastic syndrome (MDS) or after cytotoxic chemotherapy for an unrelated neoplasm. Mutations in ASXL1, BCOR, EZH2, …

it (code pays fourni par la source)

Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.

Carola Riva, Paola Minetto, Giovanni Marconi, Giada Zecchetti et autres

Abstract Introduction and aims Acute Myeloid Leukemia (AML) is a heterogeneous disease, driven by the serial acquisition of somatic mutations. Recent evidence has demonstrated that mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 are independently associated with a …

it (code pays fourni par la source)

The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.

Paola Minetto, Carola Riva, Enrico Carminati, Giada Zecchetti et autres

Abstract Background: Acute myeloid leukaemia (AML) with mutated Nucleophosmin 1 (NPM1) is recognized as a distinct subtype of AML in the 2022 WHO and ICC classification, characterized by favourable clinical outcome. However, evidence from studies shown that NPM-mut AML shows biological heterogeneity …

it (code pays fourni par la source)

CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.

Fabio Guolo, Carola Riva, Enrico Carminati, Giada Zecchetti et autres

Abstract Background and aims: The definition of secondary Acute Myeloid Leukemia (s-AML) has significantly changed from the previous WHO classification in 2016 to the recent 2022 edition. In the previous WHO 2016 classification, s-AML was defined cytogenetically, if myelodysplasia (MDS) related abnormalities …

it (code pays fourni par la source)

CT and MR in peritoneal malignancies: pearls and pitfalls at preoperative examination

Michela Polici, Federica Palmeri, Erica Golia, Emanuela Parri et autres

Peritoneal malignancies (PM) are defined as the spread of malignant epithelial cells in the peritoneal cavity. Until the recent past, the prognosis was considered extremely poor, and the treatment options had only palliative intent. Currently, new locoregional treatments have radically changed the …

it (code pays fourni par la source)

Comparing Outcomes Between CPX‐351 and Fludarabine‐Based Induction in Secondary Acute Myeloid Leukemia in the Real‐World Setting: The Prognostic Role of Measurable Residual Disease

Carola Riva, Paola Minetto, Maria Chies, Chiara Vernarecci et autres

Secondary acute myeloid leukemia (s-AML) is associated with inferior outcomes with conventional chemotherapy, and fludarabine combinations (FLAG-Ida) have been tested to improve results. More recently, CPX-351 resulted superior to conventional 3 + 7 in s-AML patients. In the UK NCRI AML19 trial, …

it (code pays fourni par la source)

Author response for "Comparing Outcomes Between CPX‐351 and Fludarabine‐Based Induction in Secondary Acute Myeloid Leukemia in the Real‐World Setting: The Prognostic Role of Measurable Residual Disease"

Carola Riva, Paola Minetto, Maria Chies, Chiara Vernarecci et autres

Excellent Outcome in NPM1-mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Paola Minetto, Carola Riva, Enrico Carminati, Ylenia Azzanelli et autres

Background: AML with mutated NPM1 (NPM mut AML) represents a distinct subtype of AML generally characterized by favourable prognosis. Nevertheless, several studies disclosed a biological and molecular heterogeneity of NPM mut AML. Despite only FLT3-ITD mutation and adverse karyotype are currently validated …

it (code pays fourni par la source)

High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction

Fabio Guolo, Carola Riva, Maria Chies, Chiara Vernarecci et autres

Background and aims The better understanding of the molecular basis of Acute Myeloid Leukemia (AML) allowed to identify critical gene mutations related to a higher risk of treatment failure in patients receiving conventional 3+7 chemotherapy. Consequently, the presence of at least one …

it (code pays fourni par la source)

Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification

Carola Riva, Paola Minetto, Maria Chies, Chiara Vernarecci et autres

Background and aims: Advances in understanding of Acute Myeloid Leukemia (AML) ontogeny are leading to a switch from a clinical to a molecular definition of secondary AML (s-AML). This is reflected by the WHO 2022 classification, where s-AML is hierarchically defined by …

it (code pays fourni par la source)

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Chiara Vernarecci, Elena Maio, Mattia Montanari, Francesco Puglisi et autres

Background: Treatment of acute lymphoblastic leukemia (ALL) in adults has historically shown unsatisfactory outcomes when compared to the outstanding results obtained in pediatric patients. Pediatric protocols rely on increased drug intensity and on a tighter evaluation of minimal residual disease (MRD) for …

it (code pays fourni par la source)

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Carola Riva, Paola Minetto, Enrico Carminati, Maria Chies et autres

Background: CPX-351 has recently been approved for the treatment of patients diagnosed with Acute Myeloid Leukemia (AML) arising from a previous myelodisplastic syndrome (s-AML) or secondary to chemotherapy (t-AML) as per former WHO 2016 classification. Minimal residual disease (MRD) assessment is a …

it (code pays fourni par la source)